3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Acrocephalosyndactylia
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Neoplasms
1
Liver Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Transitional Cell
1
Biliary Tract Neoplasms
1
Interventions
pembrolizumab
26
Nivolumab
10
Cisplatin
9
Gemcitabine
8
Docetaxel
6
enfortumab vedotin
5
atezolizumab
5
Ipilimumab
5
Carboplatin
5
sacituzumab govitecan
4
Paclitaxel
4
Pemetrexed
3
Cyclophosphamide
3
vofatamab
2
tremelimumab
2
tislelizumab
2
regorafenib
2
lenvatinib
2
epacadostat
2
durvalumab
2
avelumab
2
Specimen Handling
2
Magnetic Resonance Spectroscopy
2
Leucovorin
2
Biopsy
2
Bevacizumab
2
B701 protein, Human herpesvirus 6
2
ALT-803
2
yeast-CEA vaccine
1
toripalimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Carcinoma, Transitional Cell
×
derazantinib
×
Clear all
NCT04045613
2023-10-13
FIDES-02
Basilea Pharmaceutica
Phase 1/2
Completed
95 enrolled
25 charts